Abstract
Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth
Highlights
We surveyed all the premenopausal breast cancer patients in our hospital
Five patients were treated with 20-30 mg of tamoxifen daily (ABIC Chemical and Pharmaceutical Industries, Netanya, Israel) for a period of 6-18 months
Tamoxifen treatment was discontinued in a third patient, in whom a gradual reduction in the size of the ovarian cysts occurred until they completely disappeared 2 months later, with a concomitant decrease in oestradiol levels
Summary
We surveyed all the premenopausal breast cancer patients in our hospital. Five other similar patients were not receiving tamoxifen. None of the patients had received any hormonal treatment.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
